FDA Panel Recommends Pfizer Booster Shots for People 65+ and Especially Vulnerable

Liesl Eibschutz, a medical student from Dartmouth University, loads a syringe with the Pfizer Covid-19 vaccine at Kedren Health in Los Angeles, California on April 15, 2021. (Photo: Allen J. Schaben/Los Angeles Times via Getty Images)

FDA Panel Recommends Pfizer Booster Shots for People 65+ and Especially Vulnerable

The scientific advisory committee voted down a recommendation for other adults.

A Food and Drug Administration advisory panel on Friday unanimously recommended booster shots of the Pfizer Covid-19 vaccine for U.S. adults age 65 and older, and those especially at risk from virus, while voting strongly against recommending the same for people between the ages of 16 and 64.

Though neither vote is binding, the agency is likely to follow the advice of the 18-member committee and is expected to issue a final decision on boosters--a topic of controversy in recent months, especially given the ongoing global inequity in terms of access to vaccines--as early as next week.

According to the Associated Press:

The decision was made by a committee of outside experts who advise the Food and Drug Administration.

In a surprising turn, the panel first rejected, by a vote of 16-2, boosters for nearly everyone.

Members cited a lack of safety data on extra doses and also raised doubts about the value of mass boosters, rather than ones targeted to specific groups. Then, in an 18-0 vote, it endorsed the extra shot for select portions of the U.S. population--namely, those most at risk from the virus.

While the Biden administration had set a public goal of enacting a booster program for all U.S. adults this fall, there has been consistent pushback from the scientific community over whether the evidence supported the need for such a sweeping policy.

"It's unclear that everyone needs to be boosted, other than a subset of the population that clearly would be at high risk for serious disease," Dr. Michael G. Kurilla, a committee member and official at the National Institutes of Health, told the New York Times.

Dr. Ashish Jha, the dean of the Brown University School of Public Health, welcomed the panel's position, tweeting Friday that it is "clearly consistent with the evidence and this outcome should never have been in doubt."

Join Us: News for people demanding a better world


Common Dreams is powered by optimists who believe in the power of informed and engaged citizens to ignite and enact change to make the world a better place.

We're hundreds of thousands strong, but every single supporter makes the difference.

Your contribution supports this bold media model—free, independent, and dedicated to reporting the facts every day. Stand with us in the fight for economic equality, social justice, human rights, and a more sustainable future. As a people-powered nonprofit news outlet, we cover the issues the corporate media never will. Join with us today!

Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.